Pelvic Congestion Syndrome Treatment Market Rising Demand from Developing Nations Influencing Market Growth in the Coming Years 2018 to 2028 // Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius K

Pelvic congestion syndrome is a common issue among women between the 20 and 50 years of age. Mostly doctors prescribed painkillers for pelvic congestion syndrome treatment to reduce the pain. Apart from this hormonal therapy is also given to reduce the congestion in pelvic congestion syndrome treatment. Various treatment procedures in pelvic congestion syndrome treatment expected to drive the market. Hormonal treatment helps to reduce congestion and blood flow of the viscous vein. If these pelvic congestion syndrome treatment fails, minimally invasive therapies such as nonsurgical embolization are mostly used in pelvic congestion syndrome treatment. Advancement in latest technologies and procedures is likely anticipate to boost the pelvic congestion syndrome treatment market. Lack of skilled professional and lack of awareness among people may restrain the growth of Pelvic Congestion Syndrome Treatment Market. Cost of embolization procedures is also another factor that may hinder the pelvic congestion syndrome treatment market.

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=3127

Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities. According to a study reported in 2016, it is estimated that 10 million women suffer from pelvic congestion syndrome with approximately 7 million women avoid seeking treatment. Worldwide prevalence of chronic pelvic pain is estimated to vary from 26.6% in Egypt and 5.7% in Austria. The economic scenario of the pelvic congestion syndrome has a great impact. The annual medical cost of pelvic congestion syndrome diagnosis and pelvic congestion syndrome treatment is estimated to be around US$ 1.2 billion and the cost of lost productivity in patients with pelvic congestion syndrome treatment is estimated to be around US$ 15 billion annually.

Pelvic Congestion Syndrome Treatment Market: Overview

Pelvic congestion syndrome treatment market is expected to have gradual growth. Medical pelvic congestion syndrome treatment includes danazol, psychotherapy, progestin, phlebotonics, gonadotropins receptor agonists (GnRH) which is done by hormone replacement therapy, nonsteroidal anti-inflammatory drugs, and dihydroergotamine. Also some of the latest technologies which consists of transcatheter embolotherapy is being currently used in pelvic congestion syndrome treatment. Medical therapy has shown to provide relief to the patients but the outcome is for a shorter period. However, Gonadotrophin releasing hormone agonist called goserelin has shown satisfactory results in pelvic congestion syndrome treatment pain. Apart from this, hysterectomy with oophorectomy has proven to provide moderate relief to patients with pelvic congestion syndrome treatment. Embolotherapy has been an exciting therapy in pelvic congestion syndrome treatment. With advances in medical sciences, pelvic congestion syndrome treatment market expected to have significant growth in next few years.

To know more about the Pelvic Congestion Syndrome Treatment Market Visit the link- https://www.factmr.com/report/3127/pelvic-congestion-syndrome-treatment-market

Pelvic Congestion Syndrome Treatment Market: Region-wise Outlook

On the basis of geography, the global pelvic congestion syndrome treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa. North America is expected to dominate the global pelvic congestion syndrome treatment market due to advancement in technology, high healthcare facilities and improve infrastructure which will facilitate the growth of pelvic congestion syndrome treatment market. Europe is also likely anticipate to boost the overall growth of pelvic congestion syndrome treatment market owing to adoption of new treatment options and availability of drugs and increase in procedures of injectable used for the pelvic congestion syndrome treatment. Asia Pacific is expected to have the potential to drive the global pelvic congestion syndrome treatment market due to increase in prevalence of pelvic congestion syndrome. According to one report, the prevalence rate of chronic pelvic pain in developing countries accounts to 5.2% in India and 43.2% in Thailand. Among these cases, pelvic congestion syndrome reports 16% to 31% of all cases which is likely to have a considerable growth in pelvic congestion syndrome treatment market. Middle East and Africa has less potential to drive the pelvic congestion syndrome treatment market due to lack of awareness among people and poor healthcare facilities may restrain the growth of the pelvic congestion syndrome treatment market.

Pelvic Congestion Syndrome Treatment Market: Key Players

Some of the key players present across the value chain of the global pelvic congestion syndrome treatment market are Sanofi, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius Kabi USA,LLC.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=3127

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.